Slowly Progressive Limb-Girdle Weakness and HyperCKemia - Limb Girdle Muscular Dystrophy or Anti-3-Hydroxy-3-Methylglutaryl-CoA-Reductase-Myopathy?
Limb-girdle dystrophy
anti-HMGCR-myopathy
immunoglobulins
muscle biopsy
Journal
Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
28
6
2022
medline:
14
9
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)-myopathy is a usually rapidly progressive form of immune-mediated necrotizing myopathy (IMNM). Rarer clinical courses show slow progression and resemble the phenotype of limb-girdle dystrophy (LGMD). We demonstrate the difficulties in differentiating LGMD versus anti-HMGCR-myopathy. We report on a 48-year-old patient with slowly progressive tetraparesis and hyperCKemia for more than 20 years. Due to myopathic changes in initial and second muscle biopsy and typical clinical presentation, the patient was diagnosed with LGMD 20 years ago; despite comprehensive genetic testing including exome diagnostics, the genetic cause of disease could not be identified. Finally, HMG-CoA reductase antibodies were detected, confirming the diagnosis of anti-HMGCR-myopathy. By re-work-up of a second muscle biopsy specimen from year 2009, the diagnosis of a IMNM was made in retrospect. Seven cycles of high-dose immunoglobulins were administered; patient reported outcome measures have mildly improved. Patients with clinical LGMD phenotype, degenerative changes in muscle biopsy but without genetic confirmation of the disease should be tested for HMG-CoA-myopathy, thereby allowing for an early start of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)-myopathy is a usually rapidly progressive form of immune-mediated necrotizing myopathy (IMNM). Rarer clinical courses show slow progression and resemble the phenotype of limb-girdle dystrophy (LGMD).
OBJECTIVE
OBJECTIVE
We demonstrate the difficulties in differentiating LGMD versus anti-HMGCR-myopathy.
METHODS
METHODS
We report on a 48-year-old patient with slowly progressive tetraparesis and hyperCKemia for more than 20 years.
RESULTS
RESULTS
Due to myopathic changes in initial and second muscle biopsy and typical clinical presentation, the patient was diagnosed with LGMD 20 years ago; despite comprehensive genetic testing including exome diagnostics, the genetic cause of disease could not be identified. Finally, HMG-CoA reductase antibodies were detected, confirming the diagnosis of anti-HMGCR-myopathy. By re-work-up of a second muscle biopsy specimen from year 2009, the diagnosis of a IMNM was made in retrospect. Seven cycles of high-dose immunoglobulins were administered; patient reported outcome measures have mildly improved.
CONCLUSION
CONCLUSIONS
Patients with clinical LGMD phenotype, degenerative changes in muscle biopsy but without genetic confirmation of the disease should be tested for HMG-CoA-myopathy, thereby allowing for an early start of treatment.
Identifiants
pubmed: 35754285
pii: JND220810
doi: 10.3233/JND-220810
doi:
Substances chimiques
Autoantibodies
0
Oxidoreductases
EC 1.-
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM